BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Nov 25, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Rizatriptan regulatory update

RedHill Biopharma plans to submit an MAA next half in Europe for RHB-103 to treat acute migraine under the Mutual Recognition Procedure following a "positive" meeting with Germany's Federal Institute for Drugs and Medical Devices (BfArM). Germany will...

Read the full 167 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >